Search

Displaying results 961 - 970 of 10000 in total
  1. Drug

    PPL-100

    go.drugbank.com/drugs/DB05961
    Investigational

  2. Drug

    ANZ-100

    go.drugbank.com/drugs/DB05967
    Investigational

  3. Drug

    Archexin

    go.drugbank.com/drugs/DB05971
    Investigational

    Synonyms: 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', SODIUM PHOSPHOTHIOATE
  4. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  5. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.

    Synonyms: WT-1 analog peptide vaccine
  7. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  8. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    1 (IGF-1). … [L64112] The European Commission granted marketing authorization on August 24, 2026 for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged 5 years and older

    Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: glycyl-L-2-methylprolyl-L-glutamic acid
  9. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).